Showing 3131-3140 of 7058 results for "".
Take 5: Recent Developments in Systemic Therapy for Psoriasis
https://practicaldermatology.com/columns/recent-developments/take-5-recent-developments-in-systemic-therapy-for-psoriasis/22002/New data reveal noteworthy financial and clinical trends in the use of systemic agents.New Frontiers in Skin Cancer Management
https://practicaldermatology.com/topics/skin-cancer-photoprotection/new-frontiers-in-skin-cancer-management/57249/Across the spectrum of diagnosis, prognostication, prevention, and treatment, advances in technology and therapeutics are reshaping how clinicians care for patients with skin cancer. This issue highlights innovations and insights that are changing the field and offers a glimpse of where skin cancerMalassezia Sensitization in Head and Neck Atopic Dermatitis: A Meta-Analysis of Prevalence and Diagnostic Markers
https://practicaldermatology.com/topics/atopic-dermatitis/malassezia-sensitization-in-head-and-neck-atopic-dermatitis-a-meta-analysis-of-prevalence-and-diagnostic-markers/57253/In the 2024 study by See Tow and Yew entitled, “Malassezia specific IgE in head and neck dermatitis of eczema: A systematic review & meta-analysis,” the authors found no statistically significant differences in prevalence of dominant Malassezia species but concluded that Malassezia-specific IgEPrecision Medicine for AD
https://practicaldermatology.com/columns/atopic-dermatitis-essentials/precision-medicine-for-ad/54826/A Q & A with Derek MaetzoldRemaking Ourselves: Aesthetic Medicine That Is Regenerative
https://practicaldermatology.com/issues/october-2025/remaking-ourselves-aesthetic-medicine-that-is-regenerative/39752/First Reported Case of Red Face Response to Tralokinumab in the United States
https://practicaldermatology.com/issues/september-2025/first-reported-case-of-red-face-response-to-tralokinumab-in-the-united-states/37639/The chronic nature of atopic dermatitis (AD), which currently affects approximately 10.8% of children and 7.3% of adults in the United States,1 makes long-term management challenging.Comorbidities in Immune-mediated Skin Disorders: What’s Coming
https://practicaldermatology.com/issues/january-february-2025/comorbidities-in-immune-mediated-skin-disorders-whats-coming/32968/Comorbidities in immune-mediated skin disorders (IMSDs) occur frequently and have a significant impact on disease severity, treatment, prognosis, and quality of life.An Exciting Integration of Two Cosmetic Conferences
https://practicaldermatology.com/topics/editorial/exciting-integration-two-cosmetic-conferences/28865/After 13 years of running Cosmetic Surgery Forum on my own, I am excited to announce the integration of Cosmetic Surgery Forum into the Multispecialty Aesthetic Conference (MAC), to be held in Hilton Head from March 27-30, 2025 at the oceanfront Westin Hilton Head Island Resort.Developing Core Outcome Sets: The Importance of Common Standards for Clinical Studies of Specific Diseases and Conditions
https://practicaldermatology.com/topics/feature/developing-core-outcome-sets-importance-common-standards-clinical-studies-specific-diseases-and-conditions/26654/Developing Core Outcome Sets: The Importance of Common Standards for Clinical Studies of Specific Diseases and ConditionsEmbrace Your Curiosity: The Power of Questions
https://practicaldermatology.com/topics/practice-management/embrace-your-curiosity-the-power-of-questions/24031/Asking empowering questions may yield more creative answers.